HomeCompareHLUYY vs ORCC

HLUYY vs ORCC: Dividend Comparison 2026

HLUYY yields 21.52% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLUYY wins by $58.7K in total portfolio value
10 years
HLUYY
HLUYY
● Live price
21.52%
Share price
$22.00
Annual div
$4.73
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$7,902.94
Full HLUYY calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — HLUYY vs ORCC

📍 HLUYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUYYORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUYY + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUYY pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUYY
Annual income on $10K today (after 15% tax)
$1,829.43/yr
After 10yr DRIP, annual income (after tax)
$6,717.50/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, HLUYY beats the other by $6,716.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUYY + ORCC for your $10,000?

HLUYY: 50%ORCC: 50%
100% ORCC50/50100% HLUYY
Portfolio after 10yr
$50.8K
Annual income
$3,951.99/yr
Blended yield
7.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

HLUYY
Analyst Ratings
1
Hold
Consensus: Hold
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUYY buys
0
ORCC buys
0
No recent congressional trades found for HLUYY or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUYYORCC
Forward yield21.52%9.79%
Annual dividend / share$4.73$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$80.1K$21.4K
Annual income after 10y$7,902.94$1.04
Total dividends collected$47.3K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: HLUYY vs ORCC ($10,000, DRIP)

YearHLUYY PortfolioHLUYY Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$12,852$2,152.27$11,190$489.61+$1.7KHLUYY
2$16,337$2,585.20$12,229$256.01+$4.1KHLUYY
3$20,552$3,071.18$13,216$130.74+$7.3KHLUYY
4$25,601$3,610.76$14,207$66.02+$11.4KHLUYY
5$31,597$4,203.63$15,234$33.17+$16.4KHLUYY
6$38,657$4,848.69$16,317$16.62+$22.3KHLUYY
7$46,908$5,544.07$17,468$8.32+$29.4KHLUYY
8$56,478$6,287.15$18,695$4.16+$37.8KHLUYY
9$67,506$7,074.71$20,006$2.08+$47.5KHLUYY
10$80,135$7,902.94$21,407$1.04+$58.7KHLUYY

HLUYY vs ORCC: Complete Analysis 2026

HLUYYStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUYY Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this HLUYY vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUYY vs SCHDHLUYY vs JEPIHLUYY vs OHLUYY vs KOHLUYY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.